These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18796411)

  • 1. FDA approves thrombopoiesis-stimulating agent.
    Thompson CA
    Am J Health Syst Pharm; 2008 Oct; 65(19):1788. PubMed ID: 18796411
    [No Abstract]   [Full Text] [Related]  

  • 2. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet production bolstered with romiplostim approval.
    Morrow T
    Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune thrombocytopenic purpura--the changing therapeutic landscape.
    Bromberg ME
    N Engl J Med; 2006 Oct; 355(16):1643-5. PubMed ID: 17050888
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel thrombopoietic agents: preliminary activity, potential benefit.
    Bussel JB
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):63-84. PubMed ID: 17550056
    [No Abstract]   [Full Text] [Related]  

  • 6. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
    Nichol JL
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoiesis: new ITP paradigm?
    Despotovic JM; Ware RE
    Blood; 2011 Jul; 118(1):1-2. PubMed ID: 21737604
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
    Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
    J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
    Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
    Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim.
    Cines DB; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Nov; 7(11):887-8. PubMed ID: 18974747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].
    Mingot Castellano ME
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():39-43. PubMed ID: 21381287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The REMS publication paradox.
    Andrews EB; Kaye JA; Van Bennekom C
    Oncology (Williston Park); 2009 Jul; 23(8):715-7. PubMed ID: 19711587
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustaining platelet counts in chronic ITP.
    Nurden AT
    Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract]   [Full Text] [Related]  

  • 17. Romiplostim: a novel thrombopoiesis-stimulating agent.
    Perreault S; Burzynski J
    Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 20. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
    Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
    N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.